Davide Melisi

机构：University of Verona, Azienda Ospedaliera Universitaria Integrata Verona · ORCID：0000-0002-4031-7585

发表论文 439 篇 · 总被引 10287 次 · h-index 50

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 32)
• Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC). (2026 · Journal of Clinical Oncology · 被引 10)
• Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial (2025 · Annals of Oncology · 被引 8)
• MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors. (2025 · Journal of Clinical Oncology · 被引 6)
• Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial (2025 · ESMO Open · 被引 5)
• Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial (2026 · Journal of Clinical Oncology · 被引 4)